IC
OLMA icon

Inscription Capital’s Olema Pharmaceuticals OLMA Stock Holding History

Inscription Capital’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$191K Hold
15,273
– – 0.02% 718
2026
Q1 		$228K Hold
15,273
– – 0.02% 577
2025
Q4 		$382K Buy
+15,273
New +$272K 0.04% 435

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Inscription Capital's OLMA Position: Q2 2026 in Review

Inscription Capital held its Olema Pharmaceuticals (OLMA) position steady in Q2 2026 at 15,273 shares worth $191K. The position accounts for 0.02% of the portfolio, ranked #718.

Inscription Capital first reported a position in OLMA in Q4 2025 and has held it in 3 quarters since. The position peaked at $382K in Q4 2025. 186 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • Inscription Capital held 15,273 shares of Olema Pharmaceuticals worth $191K as of Q2 2026.
  • Inscription Capital left its Olema Pharmaceuticals share count unchanged in Q2 2026.
  • Olema Pharmaceuticals made up 0.02% of Inscription Capital's portfolio in Q2 2026, its #718 holding.
  • Inscription Capital first reported a position in Olema Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Inscription Capital's Olema Pharmaceuticals position peaked at $382K in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on Inscription Capital's 13F filing for Q2 2026, filed 13 Aug 2026.